Related Experiment Video
Updated: May 15, 2025

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types
1Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, Frankfurt/Main, Germany.
This review introduces a new typology for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) liver injury, categorizing cases by cause and diagnostic method. This classification aims to improve understanding and treatment of SJS/TEN liver injury.
Area of Science:
- Dermatology
- Hepatology
- Pharmacovigilance
Background:
- Liver injury is a complex complication of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- Causes are diverse, including drugs, heavy metals, infections, and radiation, leading to diagnostic challenges.
- SJS/TEN represents a spectrum of immune-mediated disorders, with TEN being the most severe form.
Purpose of the Study:
- To analyze diagnostic algorithms for causality assessment in SJS/TEN liver injury.
- To characterize different types of SJS/TEN liver injury based on etiology and diagnostic methods.
- To propose a new typology for SJS/TEN to enhance homogeneity and understanding.
Main Methods:
- Extensive literature search for case reports, cohorts, and reviews.
- Inclusion of search terms: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Roussel Uclaf Causality Assessment Method (RUCAM), and Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN).
- Development of a five-type SJS/TEN typology based on culprit (drug/non-drug/unknown) and assessment tools (ALDEN/RUCAM/other).
Main Results:
- SJS/TEN liver injury lacks cohort homogeneity due to varied causes and diagnostic approaches.
- A new five-type typology for SJS/TEN is proposed: Type 1 (drug, ALDEN & RUCAM), Type 2 (drug, ALDEN only), Type 3 (drug, other tools), Type 4 (non-drug), Type 5 (unknown).
- This typology aims to standardize classification and improve characterization of SJS/TEN liver injury.
Conclusions:
- The proposed SJS/TEN typology addresses issues of inhomogeneity in liver injury classification.
- This new classification facilitates better individual feature characterization and personalized treatment strategies.
- Clarifying pathogenetic specifics for each of the five disease types is a key outcome.
Related Concept Videos
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Clinical Applications of Epidermal Stem Cells

